Table 5.

In vivo antitumor effects in H22-bearing mice (n = 10)

Drug groups	Mice body weight (g)		Tumor weight (g)	Inhibition rate (%)
	Before study	After study
Saline	19.84 ± 1.21	30.39 ± 3.24	1.88 ± 0.21	–
5-FU (25 mg/kg)	19.17 ± 1.13	24.47 ± 2.85	0.59 ± 0.17**	68.55
Blank SLN	19.42 ± 1.36	30.94 ± 4.03	1.81 ± 0.22	3.68
FMO (100 mg/kg)	20.03 ± 1.55	25.13 ± 2.31	1.26 ± 0.24**	32.94
β-CD (100 mg/kg)	19.38 ± 0.99	26.11 ± 2.50	1.22 ± 0.16**	34.8
SLN (100 mg/kg)	19.29 ± 1.37	25.23 ± 3.18	1.06 ± 0.15**,#	43.66

Notes: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.

^**P < 0.01 vs saline control group;

^#P < 0.05 vs FMO suspension group, β-CD group, and FMO-β-CD group at 100 mg/kg body weight.

Abbreviation: FMO-SLNs, frankincense and myrrh oil–solid lipid nanoparticles.